VNDA Latest Headlines

Vanda’s Top Brass Quietly Unload a Wave of Shares in Coordinated Sell-Off

at www.tipranks.com (Wed, 4-Mar 9:07 PM)

FDA Grants Landmark Hearing for HETLIOZ: First Drug Approval Hearing in Over 40 Years Raises Stakes for VNDA

Market Chameleon (Tue, 3-Mar 9:03 AM)

Vanda granted public hearing to review FDA denying Hetlioz for jet lag

at seekingalpha.com (Tue, 3-Mar 4:40 PM)

Vanda Pharmaceuticals: Limited Downside, Pipeline-Driven Upside Supports $24 Target Price

at www.tipranks.com (Mon, 2-Mar 6:36 AM)

Vanda Pharmaceuticals Sets Sights on 2026 Citizens Life Sciences Conference Participation

Market Chameleon (Fri, 27-Feb 8:56 AM)

FDA Accepts Vanda’s Imsidolimab Application—53% of Patients Achieved Clear or Almost Clear Skin in Pivotal Studies

Market Chameleon (Wed, 25-Feb 7:55 AM)

VNDA Gains FDA Nod for BYSANTI, Setting Stage for Psychiatric Treatment Innovation Through 2044 Exclusivity

Market Chameleon (Mon, 23-Feb 9:54 AM)

Vanda Pharmaceuticals Eyes Growth on Robust Fanapt® Sales and Regulatory Milestones as 2026 Approaches

Market Chameleon (Thu, 12-Feb 8:24 AM)

FDA Approves Vanda’s NEREUS—First Novel Motion Sickness Drug in 40 Years Spurs Historic Milestone

Market Chameleon (Wed, 31-Dec 9:53 AM)

FDA Application Submission for Imsidolimab Marks a Milestone for Vanda—Phase 3 Data Suggest Durable Benefits for GPP Patients

Market Chameleon (Mon, 15-Dec 11:44 AM)

Vanda's Imsidolimab Application Targets FDA Priority Review: New Hope for Generalized Pustular Psoriasis

Market Chameleon (Mon, 15-Dec 8:37 AM)

FDA Clears Path for Vanda’s Tradipitant: Clinical Hold Lifted and PDUFA Decision Looms

Market Chameleon (Fri, 5-Dec 11:10 AM)

FDA Clears Path for Vanda's Tradipitant in Motion Sickness: PDUFA Date Approaches, Marking First Major Advancement in 40 Years

Market Chameleon (Fri, 5-Dec 8:39 AM)